%PDF-1.4
%
51 0 obj
<>
endobj
48 0 obj
<>
endobj
109 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T17:14:59Z
2024-03-29T05:14:23-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T05:14:23-07:00
application/pdf
Heather
2001-841.july
uuid:08c1fa2f-1dd2-11b2-0a00-7108276d7200
uuid:08c1fa31-1dd2-11b2-0a00-b80000000000
endstream
endobj
37 0 obj
<>
endobj
38 0 obj
<>
endobj
52 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
27 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
30 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
127 0 obj
[131 0 R]
endobj
128 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.0249 Tw 8 0 0 8 61 714.5293 Tm
[(7.)-875 (V)129.2 (oit R, Schnapp )54.8 (A, Kuhn )54.8 (A, et al. )17.7 (The nucleolar transcription factor)]TJ
1.675 -1.25 Td
(mUBF is phosphorylated by casein kinase II in the C-terminal)Tj
0 -1.25 TD
(hyperacidic tail which is essential for transactivation. EMBO J)Tj
0 Tw T*
[(1992;1)36.9 (1:221)36.9 (1-8.)]TJ
0.0249 Tw -1.675 -1.25 Td
[(8.)-875 (Hempel )17.7 (WM, Cavanaugh )54.8 (AH, Hannan RD, )17.7 (T)69.8 (aylor L, Rothblum LI.)]TJ
-0.00011 Tc 1.675 -1.25 Td
[(The species-specific RNA)-220.2 (polymerase transcription factor SL-1)]TJ
0 Tc T*
[(binds to upstream binding factor)54.9 (. Mol Cell Biol 1996;16:557-63.)]TJ
-1.675 -1.25 Td
[(9.)-875 (Grummt I. Regulation of mammalian ribosomal gene transcription)]TJ
-0.00011 Tc 1.675 -1.25 Td
[(by RNA)-220.2 (polymerase I. Prog Nucl )54.8 (Acids Res Mol Biol 1999;)]TJ
0 Tc 0 Tw T*
(62:109-54.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (O\222Mahony D, Rothblum LI. Identification of two forms of the)]TJ
2.175 -1.25 Td
[(RNA)-220.2 (polymerase I transcription factor UBF)79.7 (. Proc Natl )54.8 (Acad Sci)]TJ
0 Tw T*
[(USA)-220.2 (1991;88:3180-4.)]TJ
0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, )17.7 (T)69.7 (a)-0.1 (n EM.)]TJ
0 Tc 2.1381 -1.25 Td
(Nucleolar antigens and autoantibodies in hepatocellular carcinoma)Tj
T*
[(and other malignancies. )54.9 (Am J Pathol 1992;140:859-70.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (Imai H, Fritzler MJ, Neri R, Bombardieri S, )17.7 (T)69.7 (an EM, Chan EKL.)]TJ
0 Tc 2.175 -1.25 Td
(Immunocytochemical characterization of human NOR-90)Tj
T*
(\(upstream binding factor\) and associated antigens reactive with)Tj
T*
[(autoimmune sera. Mol Biol Reports 1994;19:1)36.9 (15-24.)]TJ
-2.175 -1.25 Td
[(13.)-875 (Dick )17.7 (T)74 (, Mierau R, Sternfeld R, )17.7 (W)79.8 (einer EM, Genth E. Clinical )]TJ
2.175 -1.25 Td
[(relevance and HLA)-220.1 (associations of autoantibodies against the)]TJ
T*
[(nucleolus or)17.8 (ganizer region \(NOR-90\). J Rheumatol 1995;22:67-72.)]TJ
-2.175 -1.25 Td
[(14.)-875 (Fujii )17.7 (T)74 (,)0.1 ( Mimori )17.7 (T)74 (, )54.8 (Ahizuki M. Detection of autoantibodies to )]TJ
-0.00011 Tc 2.175 -1.25 Td
(nucleolar transcription factor NOR 90/hUBF in sera of patients)Tj
0 Tc T*
(with rheumatic diseases, by recombinant autoantigen-based assays.)Tj
T*
(Arthritis Rheum 1996;39:1313-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (Fritzler MJ, von M\374hlen CA, )17.7 (T)69.7 (o)0.1 (f)17.7 (foli SM, Staub HL, Laxer RM.)]TJ
0 Tc 2.175 -1.25 Td
[(Autoantibodies to the nucleolar or)17.8 (ganizer antigen NOR-90 in)]TJ
0.275 -1.25 Td
(children with systemic rheumatic diseases. J Rheumatol)Tj
0 Tw -0.275 -1.25 Td
(1995;22:521-4.)Tj
0.0249 Tw 30.825 37.5 Td
[(16.)-875 (Scussel-Lonzetti LS, Joyal F)79.8 (, Raynauld JP)110.8 (, et al. Updating the 1980)]TJ
2.175 -1.25 Td
(American College of Rheumatology preliminary classification)Tj
-0.00011 Tc T*
(criteria for systemic sclerosis: addition of severe nailfold capillary)Tj
0 Tc T*
(microsopy abnormalities markedly increases the sensitivity for)Tj
T*
[(limited scleroderma. )54.9 (Arthritis Rheum 2001;44:735-6.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875.1 (W)39.7 (ilken, N, Kossner U, Sen\351cal JL, Scheer U, Dabauvalle MC.)]TJ
0 Tc 2.175 -1.25 Td
(Nup180, a novel nuclear pore complex protein localizing to the)Tj
T*
(cytoplasmic ring and associated fibrils. J Cell Biol 1993;)Tj
0 Tw T*
(123:1345-53.)Tj
0.0249 Tw -2.175 -1.25 Td
[(18.)-875 (Thomas JO, Kornber)17.8 (g RD. )54.8 (An octamer of histones in chromatin)]TJ
2.175 -1.25 Td
[(and free in solution. Proc Natl )54.8 (Acad Sci USA)-220.1 (1975;72:2626-30.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (Zatsepina OV)128.8 (, )17.7 (V)129.1 (oit R, Grummt I, Spring H, Semenov MV)128.8 (,)]TJ
2.175 -1.25 Td
[(T)34.8 (rendelenbur)17.7 (g MF)79.7 (. )17.6 (The RNA)-220.2 (polymerase I-specific transcription)]TJ
0 Tc T*
(intitiation factor UBF is associated with transcriptionally active and)Tj
T*
[(inactive ribosomal genes. Chromosoma 1993;102:599-61)36.9 (1.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875.1 (Roussel P)110.7 (,)-0.1 ( )54.8 (Andr\351 C, Masson C, G\351raud G, Hernandez-V)110.7 (erdun D.)]TJ
2.175 -1.25 Td
[(Localization of the RNA)-220.2 (polymerase I transcription factor hUBF)]TJ
0 Tc T*
(during the cell cycle. J Cell Sci 1993;104:327-37.)Tj
-2.175 -1.25 Td
[(21.)-875 (W)79.8 (einer ES, Hildebrandt S, Sen\351cal JL, et al. Prognostic significance)]TJ
2.175 -1.25 Td
(of anticentromere antibodies and anti-topoisomerase I antibodies in)Tj
-0.02991 Tw T*
[(Raynaud\222)54.9 (s )-54.8 (disease. A)-219.8 (prospective )-54.9 (study)64.9 (. Arthritis )-54.8 (Rheum)]TJ
0 Tw T*
(1991;34:68-77.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (V\341zquez-Abad D, Russell CA, Cusick SM, Earnshaw )17.7 (WC,)]TJ
0 Tc 2.175 -1.25 Td
[(Rothfield NF)79.8 (. Longitudinal study of anticentromere and anti-)]TJ
T*
(topoisomerase I isotypes. Clin Immunol Immunopathol)Tj
0 Tw T*
(1995;74:257-70.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Reeves )17.7 (WH, Satoh M, Richards HB. Origins of antinuclear )]TJ
2.175 -1.25 Td
[(antibodies. In: Lahita R, editor)54.8 (. Systemic lupus erythematosus. New)]TJ
T*
[(Y)100 (ork: )54.8 (Academic Press; 1999:293-317.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
0 Tc 8 0 0 8 54.5 35.9844 Tm
[(Dagher)110.8 (, et al: )17.8 (Autoantibodies to NOR 90/hUBF)]TJ
0 Tw 60.9375 -0.0313 Td
(1547)Tj
ET
0 0 0 0 scn
/GS0 gs
101.25 59.08 407.5 -10.83 re
f*
0.5 w
101.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
98 0 obj
<>
endobj
114 0 obj
<>
endobj
60 0 obj
<>
endobj
54 0 obj
<>
endobj
56 0 obj
<>
endobj
92 0 obj
<>stream
HVpg~s""&9r9hBEOH
2A
*snKk6X&1u[5Sj
eTY$nΞ/O|/ P;nu|`~!c
Je/ bSAE~zǢxھ~e3J_IbΘ@<'.)
nrvsO*bk~ %۷|OF͞SDNW^1e^>SfhAE`^.3ܺCްeʾɄuNɲ>,F:#XO0,<XAHpyv8z$P_
OG}XZxာN+> Xk%B)AndJ+1jRz7)DǓjEh/